MICHAEL MALIZIA: Open Payments
NPI 1508357534 · JOHNS ISLAND, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,429 in 169 payments from 23 companies in 2025. Trend: 2023 $89 · 2024 $2,836 · 2025 $3,429
Food & beverage: $3,429
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 25 | $476 |
| E.R. Squibb & Sons, L.L.C. | 17 | $434 |
| Axsome Therapeutics, Inc. | 16 | $374 |
| ABBVIE INC. | 20 | $290 |
| Teva Pharmaceuticals USA, Inc. | 11 | $240 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $220 |
| Lundbeck LLC | 10 | $215 |
| Neurocrine BioSciences, Inc. | 9 | $213 |
| Otsuka America Pharmaceutical, Inc. | 11 | $189 |
| Almatica Pharma LLC | 11 | $172 |
Products named: HETLIOZ, COBENFY, Auvelity, REXULTI, VRAYLAR, CAPLYTA, INGREZZA, LOREEV XR.
Industry payments across SC — which companies pay providers there.
